01:35 AM EDT, 08/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target price to USD57 from USD65, which implies a 2025 P/E of 12.8x. This is in line with peer average and above its five-year historical forward P/E average of 12.0x, justified in our view to reflect the anticipated recovery and its strategy to focus on core areas - becoming a pure-play biopharma company. We revised our EPS estimates to EUR3.90 (from EUR4.03) for 2025 and to EUR4.23 (from EUR4.30) for 2026, considering the larger anticipated currency headwinds and our reduced expectations on margin (in view of the latest result). Our EPS estimates imply 9% growth, still a recovery from the 2% decline in 2024. We continue to expect strong Dupixent uptake and new launches to support long-term growth. While recent mixed itepekimab COPD results are disappointing as they may hinder attempts to reduce Dupixent dependency, multiple late-stage readouts through 2025-2026 including crucial tolebrutinib phase 3 results could serve as catalysts.